Table 1. Patient characteristics.
|
No. (%) of subjects
|
||||
|---|---|---|---|---|
| Characteristic | Total | Death | Median survival after SCR (months) a | P-value b |
| Age at recurrence, median 56 years (range 16–84) | ||||
| Age | 0.4877 | |||
| <56 | 543 (49.4) | 341 (62.8) | 28.0 | |
| ⩾56 | 557 (50.6) | 344 (61.8) | 29.0 | |
| Year of the data | 0.1299 | |||
| 1988–1993 | 232 (21.1) | 177 (76.3) | 23.1 | |
| 1994–2000 | 289 (26.3) | 206 (71.3) | 34.0 | |
| 2001–2006 | 579 (52.6) | 302 (52.2) | 27.7 | |
| FIGO stage | ||||
| Stage I | 148 (13.5) | 69 (46.6) | 53.4 | <0.0001 |
| Stage II | 164 (14.9) | 100 (70.0) | 37.0 | |
| Stage III | 702 (63.8) | 459 (65.4) | 25.3 | |
| Stage IV | 63 (5.7) | 45 (71.4) | 25.3 | |
| Unknown | 23 (2.1) | 12 (52.2) | 30.1 | |
| Histology | ||||
| Serous | 529 (48.1) | 375 (70.9) | 27.0 | 0.3237 |
| Mucinous | 45 (4.1) | 33 (73.3) | 20.0 | |
| Endometrioid | 126 (11.5) | 81 (64.3) | 37.0 | |
| Clear cell | 46 (4.2) | 33 (71.7) | 20.0 | |
| Others | 118 (10.7) | 89 (75.4) | 25.3 | |
| Missing | 236 (21.5) | 74 (31.4) | 31.8 | |
| Grade | 0.0001 | |||
| Grade 1 | 63 (5.7) | 32 (50.8) | 54.0 | |
| Grade 2 | 292 (26.5) | 221 (75.7) | 25.0 | |
| Grade 3 | 442 (40.2) | 317 (71.7) | 28.0 | |
| Missing | 303 (27.5) | 115 (38.0) | 31.8 | |
| Primary cytoreduction | <0.0001 | |||
| 0 cm | 287 (26.1) | 131 (45.6) | 42.0 | |
| >0 cm | 396 (36.0) | 268 (67.7) | 22.0 | |
| Missing | 417 (37.9) | 286 (68.6) | 29.0 | |
| PFI | <0.0001 | |||
| 6–23.1 months | 647 (58.8) | 450 (69.6) | 21.0 | |
| >23.1 months | 453 (41.2) | 235 (51.9) | 45.0 | |
| ECOG performance status | <0.0001 | |||
| 0 | 306 (27.8) | 133 (43.5) | 38.3 | |
| 1 | 407 (37) | 261 (64.1) | 27.0 | |
| 2 | 108 (9.8) | 80 (74.1) | 13.4 | |
| 3 | 2 (0.2) | 0 (0) | – | |
| Missing | 277 (25.2) | 211 (76.2) | 28.9 | |
| CA125 (U ml–1) | <0.0001 | |||
| ⩽251 | 512 (46.5) | 262 (51.2) | 37.7 | |
| >251 | 226 (20.5) | 154 (68.1) | 23.0 | |
| Missing | 362 (33.0) | 269 (74.3) | 26.0 | |
| Ascites | <0.0001 | |||
| Present | 174 (15.8) | 137 (78.7) | 17.0 | |
| Absent | 746 (67.8) | 405 (54.3) | 33.0 | |
| Missing | 180 (16.4) | 143 (79.4) | 29.4 | |
| Extent of recurrent disease | <0.0001 | |||
| Localised | 517 (47.0) | 261 (50.5) | 43.9 | |
| Multiple | 526 (47.8) | 385 (73.2) | 20.0 | |
| Missing | 57 (5.2) | 39 (68.4) | 28.0 | |
| Max diameter of the largest recurrent site | 0.0680 | |||
| ⩽5 cm | 501 (45.5) | 279 (55.7) | 33.2 | |
| >5 cm | 299 (27.2) | 179 (59.9) | 26.0 | |
| Missing | 300 (27.3) | 227 (75.7) | 24.4 | |
| Bowel resection during SCR | 0.7504 | |||
| None | 725 (65.9) | 460 (63.4) | 28.0 | |
| Yes | 373 (33.9) | 225 (60.3) | 29.6 | |
| Missing | 2 (0.2) | 0 (0) | – | |
| Residual disease after SCR | <0.0001 | |||
| R0 | 433 (39.4) | 179 (41.3) | 57.7 | |
| R1 | 247 (22.4) | 161 (65.2) | 27.0 | |
| R2 | 323 (29.4) | 262 (81.1) | 15.6 | |
| Missing | 97 (8.8) | 83 (85.6) | 17.0 | |
| Total | 1100 | 685 (62.3) | 28.0 | |
Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; ECOG=Eastern Cooperative Oncology Group; PFI=progression-free interval; SCR=secondary cytoreductive surgery; R0=complete resection of all visible disease; R1=remaining small volume disease of 0.1–1cm; R2=remaining disease >1cm.
a
The median survival after SCR was computed using Kaplan–Meier method.
b
Log-rank test. Missing data were ignored in the analysis.